Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07822906) titled 'Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery' on Sept. 14.

Study Type: Observational

Primary Sponsor: Peking University Cancer Hospital & Institute

Condition: Esophageal Squamous Cell Carcinoma (ESCC)

Recruitment Status: Not recruiting

Date of First Enrollment: October 1, 2026

Target Sample Size: 100

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07822906

Disclaimer: Curated by HT Syndication....